Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance

The BSAC Resistance Surveillance Standing Committee

doi:10.1093/jac/dkx207

Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance

The BSAC Resistance Surveillance Standing Committee

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Background: Like other streptococci, Streptococcus agalactiae typically has intrinsic low-level aminoglycoside resistance. High-level gentamicin resistance was seen in 2 of 1125 isolates collected in the BSAC Bacteraemia Surveillance Programme between 2001 and 2014. These organisms, both isolated in 2014, were characterized. Methods: Identifications were by latex agglutination, MICs by BSAC agar dilution and sequencing by Illumina methodology. Results: Gentamicin MICs were .1024 mg/L versus a species mode of 8mg/L; both isolates also were unusually ciprofloxacin resistant with MICs of 64mg/L versus a species mode of 1mg/L. They were distinct by sequence, but both belonged to the ST19 clone, which occurs globally. Both had aac(60)-aph(200), carried by different transposons, explaining their gentamicin resistance, and had gyrA[81:S-L];parC[79:S-Y], accounting for ciprofloxacin resistance. Conclusions: These are the first multiresistant S. agalactiae with the bifunctional AAC(60)-APH(200) enzyme to be reported in the UK for .10 years. Despite belonging to the same clonal complex, the two isolates and their resistance transposons were distinct. Both retained full susceptibility to penicillin, but any penicillin/gentamicin synergy is likely to be lost.

Original language	English
Pages (from-to)	2704-2707
Number of pages	4
Journal	Journal of Antimicrobial Chemotherapy
Volume	72
Issue number	10
DOIs	https://doi.org/10.1093/jac/dkx207
Publication status	Published - 1 Oct 2017

Bibliographical note

Funding Information:
We are grateful to all the laboratories that have contributed isolates to the BSAC Bacteraemia Surveillance Programme, to Professor Paul Heath, Professor Alan Johnson, Professor Mike Sharland and Dr Theresa Lamagni for helpful discussions on the clinical significance of resistant GBS and to Roger Daniel and Chenchal Dhami of PHE for their work in extracting DNA for sequencing. The BSAC Bacteraemia Surveillance Programme was funded by many pharmaceutical companies during the 14 years reviewed here. A full listing is available at http://www.bsacsurv.org/about/sponsors-2/. Additional characterization and sequencing of the isolates was funded internally by Public Health England (PHE).

Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jac/dkx207

Cite this

@article{bf73d6d880e048a0b91cfb389f541ef3,

title = "Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance",

abstract = "Background: Like other streptococci, Streptococcus agalactiae typically has intrinsic low-level aminoglycoside resistance. High-level gentamicin resistance was seen in 2 of 1125 isolates collected in the BSAC Bacteraemia Surveillance Programme between 2001 and 2014. These organisms, both isolated in 2014, were characterized. Methods: Identifications were by latex agglutination, MICs by BSAC agar dilution and sequencing by Illumina methodology. Results: Gentamicin MICs were .1024 mg/L versus a species mode of 8mg/L; both isolates also were unusually ciprofloxacin resistant with MICs of 64mg/L versus a species mode of 1mg/L. They were distinct by sequence, but both belonged to the ST19 clone, which occurs globally. Both had aac(60)-aph(200), carried by different transposons, explaining their gentamicin resistance, and had gyrA[81:S-L];parC[79:S-Y], accounting for ciprofloxacin resistance. Conclusions: These are the first multiresistant S. agalactiae with the bifunctional AAC(60)-APH(200) enzyme to be reported in the UK for .10 years. Despite belonging to the same clonal complex, the two isolates and their resistance transposons were distinct. Both retained full susceptibility to penicillin, but any penicillin/gentamicin synergy is likely to be lost.",

author = "{The BSAC Resistance Surveillance Standing Committee} and Michel Doumith and Shazad Mushtaq and Veronique Martin and Aiysha Chaudhry and Rachael Adkin and Juliana Coelho and Victoria Chalker and Alasdair MacGowan and Neil Woodford and David Livermore",

note = "Funding Information: We are grateful to all the laboratories that have contributed isolates to the BSAC Bacteraemia Surveillance Programme, to Professor Paul Heath, Professor Alan Johnson, Professor Mike Sharland and Dr Theresa Lamagni for helpful discussions on the clinical significance of resistant GBS and to Roger Daniel and Chenchal Dhami of PHE for their work in extracting DNA for sequencing. The BSAC Bacteraemia Surveillance Programme was funded by many pharmaceutical companies during the 14 years reviewed here. A full listing is available at http://www.bsacsurv.org/about/sponsors-2/. Additional characterization and sequencing of the isolates was funded internally by Public Health England (PHE). Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2017",

month = oct,

day = "1",

doi = "10.1093/jac/dkx207",

language = "English",

volume = "72",

pages = "2704--2707",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance

AU - The BSAC Resistance Surveillance Standing Committee

AU - Doumith, Michel

AU - Mushtaq, Shazad

AU - Martin, Veronique

AU - Chaudhry, Aiysha

AU - Adkin, Rachael

AU - Coelho, Juliana

AU - Chalker, Victoria

AU - MacGowan, Alasdair

AU - Woodford, Neil

AU - Livermore, David

N1 - Funding Information: We are grateful to all the laboratories that have contributed isolates to the BSAC Bacteraemia Surveillance Programme, to Professor Paul Heath, Professor Alan Johnson, Professor Mike Sharland and Dr Theresa Lamagni for helpful discussions on the clinical significance of resistant GBS and to Roger Daniel and Chenchal Dhami of PHE for their work in extracting DNA for sequencing. The BSAC Bacteraemia Surveillance Programme was funded by many pharmaceutical companies during the 14 years reviewed here. A full listing is available at http://www.bsacsurv.org/about/sponsors-2/. Additional characterization and sequencing of the isolates was funded internally by Public Health England (PHE). Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background: Like other streptococci, Streptococcus agalactiae typically has intrinsic low-level aminoglycoside resistance. High-level gentamicin resistance was seen in 2 of 1125 isolates collected in the BSAC Bacteraemia Surveillance Programme between 2001 and 2014. These organisms, both isolated in 2014, were characterized. Methods: Identifications were by latex agglutination, MICs by BSAC agar dilution and sequencing by Illumina methodology. Results: Gentamicin MICs were .1024 mg/L versus a species mode of 8mg/L; both isolates also were unusually ciprofloxacin resistant with MICs of 64mg/L versus a species mode of 1mg/L. They were distinct by sequence, but both belonged to the ST19 clone, which occurs globally. Both had aac(60)-aph(200), carried by different transposons, explaining their gentamicin resistance, and had gyrA[81:S-L];parC[79:S-Y], accounting for ciprofloxacin resistance. Conclusions: These are the first multiresistant S. agalactiae with the bifunctional AAC(60)-APH(200) enzyme to be reported in the UK for .10 years. Despite belonging to the same clonal complex, the two isolates and their resistance transposons were distinct. Both retained full susceptibility to penicillin, but any penicillin/gentamicin synergy is likely to be lost.

AB - Background: Like other streptococci, Streptococcus agalactiae typically has intrinsic low-level aminoglycoside resistance. High-level gentamicin resistance was seen in 2 of 1125 isolates collected in the BSAC Bacteraemia Surveillance Programme between 2001 and 2014. These organisms, both isolated in 2014, were characterized. Methods: Identifications were by latex agglutination, MICs by BSAC agar dilution and sequencing by Illumina methodology. Results: Gentamicin MICs were .1024 mg/L versus a species mode of 8mg/L; both isolates also were unusually ciprofloxacin resistant with MICs of 64mg/L versus a species mode of 1mg/L. They were distinct by sequence, but both belonged to the ST19 clone, which occurs globally. Both had aac(60)-aph(200), carried by different transposons, explaining their gentamicin resistance, and had gyrA[81:S-L];parC[79:S-Y], accounting for ciprofloxacin resistance. Conclusions: These are the first multiresistant S. agalactiae with the bifunctional AAC(60)-APH(200) enzyme to be reported in the UK for .10 years. Despite belonging to the same clonal complex, the two isolates and their resistance transposons were distinct. Both retained full susceptibility to penicillin, but any penicillin/gentamicin synergy is likely to be lost.

UR - http://www.scopus.com/inward/record.url?scp=85030683910&partnerID=8YFLogxK

U2 - 10.1093/jac/dkx207

DO - 10.1093/jac/dkx207

M3 - Article

C2 - 29091185

AN - SCOPUS:85030683910

SN - 0305-7453

VL - 72

SP - 2704

EP - 2707

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 10

ER -

Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this